Latest Breaking News On - ஜப்பான் நீரிழிவு நோய் சமூகம் - Page 2 : vimarsana.com

Press release content from Business Wire. The AP news staff was not involved in its creation. Poxel Reports Financial Update for Cash and Revenue for the Full Year 2020 and Provides Corporate Update February 12, 2021 GMT LYON, France (BUSINESS WIRE) Feb 12, 2021 POXEL SA (Euronext: POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and non-alcoholic steatohepatitis (NASH), today announced its cash position and revenue for the twelve months ended December 31, 2020 and provided a corporate update. ADVERTISEMENT “Despite the challenges posed by the COVID-19 pandemic, Poxel ended 2020 on a strong note, having accomplished several important corporate and clinical milestones and positioning the Company for an exciting 2021. We continued working closely with our partner Sumitomo Dainippon Pharma to further advance the review of the Japanese New Drug Application for Imeglimin follo

United statesSouth koreaArthur rouillThomas kuhnSumitomo dainippon pharmaValeria fisherStephena harrisonJonae barnesJapan diabetes societyClinical additional developmentDivision of endocrinologyDrug development summitUniversity of floridaWorld health organizationTrophic communicationsHc wainwright global life sciences conference